WP
NGM

Woodline Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Woodline Partners’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-134,188
Closed -$1.72M – 867
2022
Q2 		$1.72M Sell
134,188
-336,851
-72% -$4.66M 0.03% 454
2022
Q1 		$7.18M Buy
+471,039
New +$7.35M 0.12% 211

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Woodline Partners's NGM Position: Q3 2022 in Review

Woodline Partners sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2022, closing a stake of 134,188 shares — an estimated $1.72M sold.

Woodline Partners first reported a position in NGM in Q1 2022 and held it in 2 quarters. The position peaked at $7.18M in Q1 2022. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

  • Woodline Partners reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Woodline Partners sold 134,188 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $1.72M.
  • Woodline Partners first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Woodline Partners's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $7.18M in Q1 2022.
  • 128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.